IFAM
RIGL icon

Institutional & Family Asset Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Institutional & Family Asset Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$82 Hold
10
– – ﹤0.01% 737
2024
Q1 		$148 Hold
10
– – ﹤0.01% 721
2023
Q4 		$145 Buy
+10
New +$102 ﹤0.01% 698

Other funds holding RIGL

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Institutional & Family Asset Management's RIGL Position: Q2 2024 in Review

Institutional & Family Asset Management held its Rigel Pharmaceuticals (RIGL) position steady in Q2 2024 at 10 shares worth $82. The position accounts for ﹤0.01% of the portfolio, ranked #737.

Institutional & Family Asset Management first reported a position in RIGL in Q4 2023 and has held it in 3 quarters since. The position peaked at $148 in Q1 2024. 91 funds tracked by Wall St. Rank hold RIGL as of Q2 2024.

  • Institutional & Family Asset Management held 10 shares of Rigel Pharmaceuticals worth $82 as of Q2 2024.
  • Institutional & Family Asset Management left its Rigel Pharmaceuticals share count unchanged in Q2 2024.
  • Rigel Pharmaceuticals made up ﹤0.01% of Institutional & Family Asset Management's portfolio in Q2 2024, its #737 holding.
  • Institutional & Family Asset Management first reported a position in Rigel Pharmaceuticals in Q4 2023 and has held it in 3 quarters since.
  • Institutional & Family Asset Management's Rigel Pharmaceuticals position peaked at $148 in Q1 2024.
  • 91 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2024.

Based on Institutional & Family Asset Management's 13F filing for Q2 2024, filed 5 Jul 2024.